Journal of Clinical and Cellular Immunology
Open Access
ISSN: 2155-9899
ISSN: 2155-9899
Alaa Abdelkarim Fouad
ACE Cells Lab Limited, UK
Keynote: J Clin Cell Immunol
The unique mixture of cellular and humoral immunity in rheumatoid arthritis (RA) that leads to activation of osteoclasts which causes the erosion of the bones and the subsequent deformity; this mixture makes RA one of the most difficult conditions to be controlled. The trigger of the inflammatory process starts by synovitis, and all the immunity process is localized in the affected joints as a harmony between the cellular immunity and the cytokines and the humoral immunity. The available treatment to control the immunity reaction is the immunosuppressants to be administered systematically while the main reaction is local reaction. Our philosophy in approaching the various conditions by giving full attention to the regeneration and repair the damage makes us give more attention here the immunity reaction which is the cause of the damage. In the RA immunity reaction we do not intend to suppress the immunity, but to modulate it and give it the proper peptides needed to neutralize the reaction in the joint. Primary research was done to 20 cases, 18 of them continued the primary 3 months course to be declared in this session showing the ability to control the immunity reaction.
Alaa Abdelkarim Fouad is the Founder and Chief Medical Officer of ACE Cells Lab Limited, UK. Consultant Endocrinology and stem cells therapy. He has more than 28 years of experience and has served in more than eight countries. He has the fellowship of Royal Society of medicine, Royal College of Chemistry, Fellowship of the Malaysian Association of Endocrinology and the International Association for Stem Cells Research. He was the Head of the Department of Endocrinology and Diabetes for more than eight years treating complications of diabetes by cellular applications.
E-mail: dralaakarim@gmail.com